Sandra D. Algaze

Assistant Professor of Clinical Medicine

Image of Sandra D. Algaze
Is this your profile? Click to edit

Overview

Dr. Sandra Algaze is an Assistant Professor of Medicine in the Division of Medical Oncology at the University of Southern California focusing on gastrointestinal cancers. Dr. Algaze completed her residency in Internal Medicine at the University of Miami, Jackson Memorial Hospital and her clinical fellowship in Hematology and Oncology at University of Southern California, Los Angeles County Hospital, where she served as a chief fellow.

Her research endeavors focus on the discovery of innovative pathways in cancer pathogenesis, metastases and treatment resistance, the development of novel therapies for gastrointestinal tumors, and the assessment of predictive and prognostic biomarkers and molecular profiles. Additionally, she is actively investigating and working to address the complexities surrounding the care of older patients with cancer, and healthcare disparities arising from barriers to specialty care access and the underrepresentation of minorities in cancer clinical trials. Notably, she was part of the inaugural cohort of the Robert A. Winn Diversity in Clinical Trials: Career Development Award (Winn CDA).

Publications

  • Long non-coding RNAs in colorectal cancer: shaping the tumour microenvironment and advancing precision oncology. Nat Rev Gastroenterol Hepatol. 2026 Sep 01.. View in PubMed
  • Dihydropyrimidine dehydrogenase modulates immune response to checkpoint inhibition in mismatch repair deficient/microsatellite instability-high colorectal cancer. J Immunother Cancer. 2026 Aug 17; 14(8).. View in PubMed
  • Next-generation precision oncology in microsatellite stable colorectal cancer: integrated targeting beyond RAS and RAF. ESMO Open. 2026 Aug; 11(8):108304.. View in PubMed
  • Activation of the endocytosis pathway stratifies subtypes and therapeutic sensitivity in colorectal cancer. Res Sq. 2026 Jul 05.. View in PubMed
  • Emerging and Established Targets in Colorectal Cancer: Translating Biology Into Therapeutics. Am Soc Clin Oncol Educ Book. 2026 Jun; 46(3):e516576.. View in PubMed
  • A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer. Cancer. 2026 Mar 15; 132(6):e70343.. View in PubMed
  • Clinical and molecular characterization of AXL in colorectal cancer, CALGB (Alliance)/SWOG 80405 and real-world data. J Immunother Cancer. 2025 Dec 21; 13(12).. View in PubMed
  • Pan-RAS inhibitors and polo-like kinase 1: promising targets in colorectal cancer. Oncogene. 2025 Aug; 44(30):2565-2573.. View in PubMed
  • Genetic Polymorphisms in MHC Classes I and II Predict Outcomes in Metastatic Colorectal Cancer. Int J Mol Sci. 2025 Mar 12; 26(6).. View in PubMed
  • Comprehensive characterization of MCL-1 in patients with colorectal cancer: Expression, molecular profiles, and outcomes. Int J Cancer. 2025 04 15; 156(8):1583-1593.. View in PubMed